Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc. is thrilled to welcome Peter Pfreundschuh as our new Chief Financial Officer and Norman LaFrance, M.D. as our Chief Development Officer. These additions further strengthen our leadership team as we work to advance our mission of improving the lives of patients with cancer and other serious diseases. Join us in welcoming Peter and Norman!   Read more about Peter here https://bit.ly/4eI6qhL and Norman here https://bit.ly/4cHp3Av   #Radiotherapy #Radiopharmaceuticals #ChildhoodCancer #PediatricOncology

We’re excited to gather at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting in Toronto, Canada starting tomorrow, June 8th through June 11th, where we will present a poster highlighting preclinical GD2-SADA data. Swing by booth #1845 and let's chat about making a difference! Read our press release for more information: https://lnkd.in/eyH7kJ8i #SNMMI #SNMMI24 #Radiotherapy

We are excited to be part of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL through June 4th. Stop by booth # 35151 and let's connect!   Poster presentations summarizing interim data from the Phase 2 Trial 201 of naxitamab will be available for viewing today, Saturday, June 1st between 1:30 p.m. and 4:30 p.m. CDT in Hall A during the #PediatricOncology track. See our full press release here: https://bit.ly/4dWlNmm   Additionally, a published abstract highlighting preclinical GD2-SADA data supports the continued clinical development of our SADA PRIT technology platform. For more information, see our press release here: https://bit.ly/3KslJ04   #ASCO2024 #ChildhoodCancer #RareDiseaseAwareness #Radiotherapy

Earlier today, Y-mAbs Therapeutics, Inc., hosted a conference call and webcast to discuss our first quarter 2024 financial results and recent corporate developments.   We continue to make key advancements across our clinical, commercial, and operational initiatives in our mission to improve the lives of patients battling cancer. Highlights from our first quarter report and corporate updates include:   - Achieved record quarterly U.S. volumes and net product sales of DANYELZA   - Y-mAbs’ distribution partner in Latin America, Adium, initiated the commercial launch of DANYELZA in Brazil and Mexico    - Reiterated full year 2024 guidance and cash runway into 2027 In addition, we look forward to presenting several abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1st. Meet us at booth #35151 on the Exhibition Floor of McCormick Place in Chicago. For more information and webcast replay details, see here: https://bit.ly/3yajSu9 #Radiopharmaceuticals #PedicatricOncology

We're gearing up for ASPHO happening in Seattle, WA on April 3 – 6, 2024. Come say hello at booth#501!  https://lnkd.in/gNYNAm7Y  #ASPHO2024 #Ymabs #PediatricCancer #RareDiseaseAwareness #childhoodcancer #cancerawareness #pediatriconcology

Counting down the days until ASPHO in Seattle, WA from April 3 – 6, 2024! Drop by booth #501 to meet our team!  https://lnkd.in/gNYNAm7Y   #2024ASPHO #Ymabs #PediatricCancer #RareDiseaseAwareness #childhoodcancer #cancerawareness #pediatriconcology

Earlier today, the Y-mAbs Therapeutics, Inc. management team held a conference call and webcast to discuss our fourth quarter and full year 2023 financial results and recent corporate developments.   We are excited by the progress made across the clinical, commercial and operational aspects of our business throughout the year, including:   - We successfully demonstrated proof-of-concept for the SADA PRIT technology platform in our GD2-SADA Phase 1 study. Additionally, the FDA cleared our IND for CD38-SADA.   - We achieved record quarterly and annual DANYELZA net product revenues and reached the high end of our full year 2023 net product revenue guidance. - Our Board of Directors appointed radiopharmaceutical veteran Michael Rossi as President and Chief Executive Officer, underscoring our commitment to drive innovation forward.   - We announced full year 2024 guidance and anticipate DANYELZA net product revenues to increase 16% at the midpoint compared to full year 2023.   As Y-mAbs reflects on a transformative 2023, we are dedicated to upholding a strong financial backbone and operational excellence that will continue to drive our mission of delivering better and safer cancer therapies to patients.   For more information and webcast replay details, see here: https://bit.ly/42X7cC6   $YMAB #Radiopharmaceuticals #PedicatricOncology

This Rare Disease Day, we acknowledge and honor the brave families fighting rare childhood cancers. At Y-mAbs Therapeutics, Inc., these families are at the forefront of our mission to provide better and safer oncology therapies and improve the lives of patients. To learn more about our mission, visit https://bit.ly/3wu5oo1, and to explore additional resources around Rare Disease Day, visit: https://bit.ly/3IefWdy #RareDiseaseDay #ChildhoodCancer #RareChildhoodCancer

We look forward to reporting our fourth quarter and full year 2023 financial results after the market close this Thursday, February 29th, followed by a conference call and webcast at 8:00 a.m. ET on Friday, March 1st.   To access the conference call and webcast details, see here: https://bit.ly/3uMVgpS   $YMAB #Radiopharmaceuticals #PedicatricOncology

Our President and CEO, Michael Rossi, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA today, Wednesday, January 10, 2024, at 5:15pm PT. Tune in to hear about recent Y-mAbs Therapeutics, Inc. developments in support of our mission to provide better and safer cancer therapies to patients. The live audio webcast can be accessed here: https://bit.ly/3NUuwdr #JPM2024 #Radiopharmaceuticals #PediatricOncology